WO2002058725A3 - Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin - Google Patents

Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin Download PDF

Info

Publication number
WO2002058725A3
WO2002058725A3 PCT/FR2002/000270 FR0200270W WO02058725A3 WO 2002058725 A3 WO2002058725 A3 WO 2002058725A3 FR 0200270 W FR0200270 W FR 0200270W WO 02058725 A3 WO02058725 A3 WO 02058725A3
Authority
WO
WIPO (PCT)
Prior art keywords
rsv
vaccine
protein
peptides derived
glycosylated peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2002/000270
Other languages
English (en)
Other versions
WO2002058725A2 (fr
Inventor
Ultan Power
Guyen Thien Ngoc N
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to EP02700379A priority Critical patent/EP1353690A2/fr
Priority to AU2002233457A priority patent/AU2002233457A1/en
Publication of WO2002058725A2 publication Critical patent/WO2002058725A2/fr
Publication of WO2002058725A3 publication Critical patent/WO2002058725A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention se rapporte au virus respiratoire syncytial, et plus particulièrement à l'identification de nouveaux antigènes non glycosylés, utiles notamment pour le traitement thérapeutique et prophylactique des affections provoquées par ce virus.
PCT/FR2002/000270 2001-01-23 2002-01-23 Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin Ceased WO2002058725A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02700379A EP1353690A2 (fr) 2001-01-23 2002-01-23 Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
AU2002233457A AU2002233457A1 (en) 2001-01-23 2002-01-23 Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/00875 2001-01-23
FR0100875A FR2819810B1 (fr) 2001-01-23 2001-01-23 Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin

Publications (2)

Publication Number Publication Date
WO2002058725A2 WO2002058725A2 (fr) 2002-08-01
WO2002058725A3 true WO2002058725A3 (fr) 2003-01-09

Family

ID=8859130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/000270 Ceased WO2002058725A2 (fr) 2001-01-23 2002-01-23 Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin

Country Status (4)

Country Link
EP (1) EP1353690A2 (fr)
AU (1) AU2002233457A1 (fr)
FR (1) FR2819810B1 (fr)
WO (1) WO2002058725A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
BR122019021416A2 (fr) * 2003-09-19 2019-12-21
EP1667724A2 (fr) * 2003-09-19 2006-06-14 Novo Nordisk A/S Nouvelles etiquettes d'affinite pour les proteines plasmiques
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
WO2011015649A1 (fr) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Hormones de croissance ayant une efficacité in vivo prolongée
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
CN106008716B (zh) 2010-07-07 2019-08-13 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
JP2025172274A (ja) * 2022-10-20 2025-11-26 一般財団法人阪大微生物病研究会 Ｒｓウイルスワクチンとしての利用に好適な組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995027787A1 (fr) * 1994-04-06 1995-10-19 Pierre Fabre Medicament Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation
WO1996014409A1 (fr) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Production de peptides recombinants, analogues de peptides naturels hydrophobes
WO1999003987A2 (fr) * 1997-07-17 1999-01-28 Pierre Fabre Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995027787A1 (fr) * 1994-04-06 1995-10-19 Pierre Fabre Medicament Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation
WO1996014409A1 (fr) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Production de peptides recombinants, analogues de peptides naturels hydrophobes
WO1999003987A2 (fr) * 1997-07-17 1999-01-28 Pierre Fabre Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
POWER U.F. ET AL.: "Differential histopathology and chemokine gene expression in lung tissues following respiratory syncitial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-imunized mice.", J. VIROL., vol. 75, no. 24, December 2001 (2001-12-01), pages 12421 - 12430, XP002203747 *
POWER U.F. ET AL.: "Induction of protective immunity in rodents by vaccination with a procaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.", VIROLOGY, vol. 230, 1997, pages 155 - 166, XP002179365 *
SIEGRIST C.A. ET AL.: "Protective efficacy aganst respiratory syncytial virus following murine neonatan immunization with BBG2Na vaccine: influence of adjuvants and materna antibodies.", J. INFECT. DIS., vol. 179, 1999, pages 1326 - 1333, XP002179366 *
SIMARD C. ET AL.: "Evidence that the amino acid region 124-203 of glycoprotein G from the respiratory syncytial virus (RSV) constitutes a major part of the polypeptide domain that is involved in the protection against RSV infection", ANTIVIRAL RES., vol. 28, no. 4, 1995, pages 303 - 305, XP000565377 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation

Also Published As

Publication number Publication date
AU2002233457A1 (en) 2002-08-06
EP1353690A2 (fr) 2003-10-22
FR2819810A1 (fr) 2002-07-26
FR2819810B1 (fr) 2004-05-28
WO2002058725A2 (fr) 2002-08-01

Similar Documents

Publication Publication Date Title
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
WO2002096937A3 (fr) Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees au substances amyloides
WO2003011899A3 (fr) Polypeptides antigeniques
WO2001039796A3 (fr) Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides
AU2002336148A1 (en) Novel peptides of the respiratory syncytial virus (RSV) G protein and their use in a vaccine
WO2001058485A3 (fr) Anticorps monoclonaux a vocation prophylactique et therapeutique
WO2002058725A3 (fr) Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
WO2006034292A3 (fr) Anticorps dirige contre le virus respiratoire syncytial et procedes de production de vaccins associes
WO2006005707A3 (fr) Methode de prevention et de traitement de la maladie d'alzheimer
WO2004080403A3 (fr) Vaccin contre le virus de la grippe
WO2004014418A3 (fr) Composition vaccinale
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
WO2002074795A3 (fr) Complexes de proteines oligomeres recombinantes a potentiel immunogene ameliore
EP1710311A3 (fr) Polypeptides antigènes
LTC1425001I2 (lt) Fenetanolamino dariniai, skirti kvėpavimo ligoms gydyti
MXPA03007262A (es) Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias.
EP1918300A3 (fr) Thérapie d'immunisation à base de peptide pour le traitement d'athérosclérose
WO2003028760A3 (fr) Vaccin
WO2005002526A3 (fr) Procedes et compositions pour le traitement d'infections virales
WO2002059143A3 (fr) Peptides therapeutiques pour troubles de la demyelinisation
ZA200205408B (en) Process for the preparation of peptides.
WO2003049765A3 (fr) Vaccin contre des virus enveloppes et methode de production
WO2003055440A8 (fr) Compositions et methodes de traitement de maladies d'origine immune
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
WO2006007555A3 (fr) Antigenes de rotavirus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN JP MX US ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002700379

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002700379

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002700379

Country of ref document: EP